Literature DB >> 10799435

Intestinal inflammation in cystic fibrosis.

R L Smyth1, N M Croft, U O'Hea, T G Marshall, A Ferguson.   

Abstract

BACKGROUND: There is controversy about whether the inflammatory response observed in the cystic fibrosis (CF) lung occurs secondary to bacterial infection or is caused by a dysregulation of the inflammatory response associated with the basic cellular defect of CF. AIMS: To study the inflammatory response in the gastrointestinal tract of children with CF; and to investigate whether there is increased inflammation in the gastrointestinal tract of CF children with fibrosing colonopathy.
METHODS: Whole gut lavage was performed on 21 pancreatic insufficient children with CF, who were clinically well, five children with CF and fibrosing colonopathy, and 12 controls. Intestinal outputs of plasma derived proteins (albumin, alpha(1) antitrypsin, IgG), secretory immunoglobulins (IgA and IgM), cellular constituents (eosinophil cationic protein and neutrophil elastase), and cytokines (interleukin 8 and interleukin 1beta) were measured.
RESULTS: Compared to controls, the 21 CF patients, with no intestinal complications, had increased intestinal outputs of albumin, IgG, IgM, eosinophil cationic protein, neutrophil elastase, interleukin 1beta, and interleukin 8. Similar values were obtained for the CF patients with fibrosing colonopathy.
CONCLUSIONS: These data suggest that there is immune activation in the gastrointestinal mucosa of children with cystic fibrosis, which may result from the basic cellular defect. Fibrosing colonopathy does not appear to be associated with increased inflammation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10799435      PMCID: PMC1718322          DOI: 10.1136/adc.82.5.394

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  36 in total

1.  Gut lavage IgG and interleukin 1 receptor antagonist:interleukin 1 beta ratio as markers of intestinal inflammation in children with inflammatory bowel disease.

Authors:  R Troncone; N Caputo; A Campanozzi; M Cucciardi; V Esposito; R Russo; B De Vizia; L Greco; S Cucchiara
Journal:  Gut       Date:  1997-07       Impact factor: 23.059

2.  Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis.

Authors:  T L Noah; H R Black; P W Cheng; R E Wood; M W Leigh
Journal:  J Infect Dis       Date:  1997-03       Impact factor: 5.226

3.  Increased concentrations of eosinophilic cationic protein in whole-gut lavage fluid from children with inflammatory bowel disease.

Authors:  R Troncone; N Caputo; V Esposito; A Campanozzi; F Campanozzi; R Auricchio; L Greco; S Cucchiara
Journal:  J Pediatr Gastroenterol Nutr       Date:  1999-02       Impact factor: 2.839

4.  Relationship between disease severity and inflammatory markers in cystic fibrosis.

Authors:  D Y Koller; M Götz; C Wojnarowski; I Eichler
Journal:  Arch Dis Child       Date:  1996-12       Impact factor: 3.791

5.  DNA fragmentation is a feature of cystic fibrosis epithelial cells: a disease with inappropriate apoptosis?

Authors:  L Maiuri; V Raia; G De Marco; S Coletta; G de Ritis; M Londei; S Auricchio
Journal:  FEBS Lett       Date:  1997-05-19       Impact factor: 4.124

6.  Cystic fibrosis gene mutation (deltaF508) is associated with an intrinsic abnormality in Ca2+-induced arachidonic acid release by epithelial cells.

Authors:  L Miele; E Cordella-Miele; M Xing; R Frizzell; A B Mukherjee
Journal:  DNA Cell Biol       Date:  1997-06       Impact factor: 3.311

7.  Direct assessment of gastrointestinal inflammation and mucosal immunity in children with cystic fibrosis.

Authors:  N M Croft; T G Marshall; A Ferguson
Journal:  Postgrad Med J       Date:  1996-03       Impact factor: 2.401

8.  Early alterations in airway mucociliary clearance and inflammation of the lamina propria in CF mice.

Authors:  J M Zahm; D Gaillard; F Dupuit; J Hinnrasky; D Porteous; J R Dorin; E Puchelle
Journal:  Am J Physiol       Date:  1997-03

9.  Inflammatory cytokines in cystic fibrosis lungs.

Authors:  T L Bonfield; J R Panuska; M W Konstan; K A Hilliard; J B Hilliard; H Ghnaim; M Berger
Journal:  Am J Respir Crit Care Med       Date:  1995-12       Impact factor: 21.405

10.  The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis.

Authors:  K Balough; M McCubbin; M Weinberger; W Smits; R Ahrens; R Fick
Journal:  Pediatr Pulmonol       Date:  1995-08
View more
  40 in total

Review 1.  The Enigmatic Gut in Cystic Fibrosis: Linking Inflammation, Dysbiosis, and the Increased Risk of Malignancy.

Authors:  Millie Garg; Chee Y Ooi
Journal:  Curr Gastroenterol Rep       Date:  2017-02

Review 2.  Beyond pancreatic insufficiency and liver disease in cystic fibrosis.

Authors:  Stephanie Demeyer; Kris De Boeck; Peter Witters; Katrien Cosaert
Journal:  Eur J Pediatr       Date:  2016-04-07       Impact factor: 3.183

3.  Azathioprine in the management of enteropathy in cystic fibrosis.

Authors:  Hui-Leng Tan; Neil Shah; Ranjan Suri
Journal:  J R Soc Med       Date:  2011-07       Impact factor: 5.344

4.  The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin.

Authors:  Manuele Furnari; Alessandra De Alessandri; Federico Cresta; Maria Haupt; Marta Bassi; Angela Calvi; Riccardo Haupt; Giorgia Bodini; Iftikhar Ahmed; Francesca Bagnasco; Edoardo Giovanni Giannini; Rosaria Casciaro
Journal:  J Gastroenterol       Date:  2018-09-19       Impact factor: 7.527

Review 5.  Fecal calprotectin use in inflammatory bowel disease and beyond: A mini-review.

Authors:  Bashaar Alibrahim; Mohammed I Aljasser; Baljinder Salh
Journal:  Can J Gastroenterol Hepatol       Date:  2015-04

Review 6.  Probiotic supplementation in children with cystic fibrosis-a systematic review.

Authors:  Anitha Ananthan; Haribalakrishna Balasubramanian; Shripada Rao; Sanjay Patole
Journal:  Eur J Pediatr       Date:  2016-08-30       Impact factor: 3.183

7.  Bacterial overgrowth in the cystic fibrosis transmembrane conductance regulator null mouse small intestine.

Authors:  Oxana Norkina; Tim G Burnett; Robert C De Lisle
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

8.  Defective goblet cell exocytosis contributes to murine cystic fibrosis-associated intestinal disease.

Authors:  Jinghua Liu; Nancy M Walker; Akifumi Ootani; Ashlee M Strubberg; Lane L Clarke
Journal:  J Clin Invest       Date:  2015-02-02       Impact factor: 14.808

9.  Epithelial IgG and its relationship to the loss of F508 in the common mutant form of the cystic fibrosis transmembrane conductance regulator.

Authors:  Kate J Treharne; Diane Cassidy; Catharine Goddard; William H Colledge; Andrew Cassidy; Anil Mehta
Journal:  FEBS Lett       Date:  2009-07-09       Impact factor: 4.124

10.  CFTR depletion results in changes in fatty acid composition and promotes lipogenesis in intestinal Caco 2/15 cells.

Authors:  Geneviève Mailhot; Rémi Rabasa-Lhoret; Alain Moreau; Yves Berthiaume; Emile Levy
Journal:  PLoS One       Date:  2010-05-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.